reports
Epsilon Energy Ltd. Schedules First Quarter 2025 Earnings Release and ...
Epsilon Energy Ltd. Schedules First Quarter 2025 Earnings Release and Conference Call HOUSTON, April 25, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced that it will issue its first quarter 2025 earnings release on Wednesday, May 14, 2025 after the market close and host a conference call to discuss its financial and operating results on Thursday, May 15, 2025 at 10:00 a.m. Central Time (11:00 a.m. Eastern Time). Interested parties in the United States and Canada may participate toll-free by dialing (833) 816-1385. International p...
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conferen...
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming CDMO Live 2025 conference. Billed as a premiere partnering event for the biopharma outsourcing industry, CDMO Live will take place May 7-8, 2025, in Rotterdam, Netherlands. During the conference, Jackie Klecker, Lifecore’s executive vice president, quality and development ...
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Lifecore granted a restricted stock unit (“RSU”) award with respect to 45,000 shares of its common stock, an option for 210,000 shares of stock, an RSU for 170,000 shares of common stock, and a performance stock unit (“PSU”) award for up to 370,000 shares of its common stock to Thomas D. Salus, Lifecore’s newly hi...
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Admini...
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer Mr. Salus Brings More than 30 Years of Broad-Based Legal and Management Expertise Highlighted by Extensive Experience within Life Sciences Industry Significantly Elevates Lifecore’s Capabilities Across Corporate Governance, Transactional Activities, and SEC Reporting and Compliance CHASKA, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has appointed Th...
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Result...
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update -- Recorded Revenues of $35.2 Million for Q3 Fiscal 2025 -- -- Signed Multiple Development Agreements with New and Existing Customers -- -- Strengthened Balance Sheet through Sale of Excess Capital Equipment, Raising Approximately $17.0 Million -- Conference Call Today at 4:30pm ET CHASKA, Minn., April 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announ...
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Vi...
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference MORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, beginning at 8:45 a.m. ET. Access to a webcast of the presentation will be available on the “Investor...
Liquidia Corporation to Present at the 24th Annual Needham Virtual Hea...
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference MORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, beginning at 8:45 a.m. ET. Access to a webcast of the presentation will be available on the “Investors” page of Liquidi...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
LOPE GRAND CANYON EDUCATION INC.
LNDC LANDEC CORP.
HOO HERBALIFE NUTRITION LTD.
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CAAS CHINA AUTOMOTIVE SYSTEMS ADS (N SHARES)
BFAM BRIGHT HORIZONS FAMILY SOLUTIONS INC.
AZO AUTOZONE INC.
ADMA ADMA BIOLOGICS INC
ACU ACME UNITED CORP.
OSTK OVERSTOCK.COM INC.
UVV UNIVERSAL CORP
FDP FRESH DEL MONTE PRODUCE INC.
TATT TAT TECHNOLOGIES LTD.
WMK WEIS MARKETS INC.
KINS KINGSTONE COS. INC.
NC NACCO INDUSTRIES INC. CL A
CHCI COMSTOCK HOLDING COMPANIES
VLGEA VILLAGE SUPER MARKET INC. CL A
LAUR LAUREATE EDUCATION INC. CLASS A
CMCL CALEDONIA MINING CORPORATION
ABT ABBOTT LABORATORIES
BRP BRP GROUP
GRPN GROUPON INC.
CNXC CONCENTRIX
DRVN DRIVEN BRANDS HOLDINGS
ALHC ALIGNMENT HEALTHCARE INC
ADSE ADS TEC ENERGY PLC
KLG_w WK KELLOGG CO
TRVG TRIVAGO N.V.
BG BUNGE LIMITED
IDR IDAHO STRATEGIC RESOURCES INC
DBD DIEBOLD NIXDORF INCORPORATED
CCB CHASE CAPITAL VIII CAP SEC H 8.25%
MNPR MONOPAR THERAPEUTICS INC.
AEVA AEVA TECHNOLOGIES INC.
ORLY OREILLY AUTOMOTIVE INC CDA
Liquidia Corporation Announces FDA Acceptance of New Drug Application ...
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder FDA sets PDUFA goal date of May 24, 2025 MORRISVILLE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pul...
Lifecore Biomedical to Report Financial Results for Third Quarter of F...
Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025 Webcast Scheduled for Thursday, April 3 at 4:30 p.m. Eastern CHASKA, Minn., March 27, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the third quarter of fiscal year 2025 on Thursday, April 3, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast to disc...
Liquidia Announces Poster Presentations at the American Thoracic Socie...
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference - Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in six-minute walk distance, cardiac effort and quality of life - Case study highlights the long-term safety and tolerability of LIQ861 (YUTREPIA) in a PAH patient transitioning from parenteral treprostinil in INSPIRE study MORRISVILLE, N.C., March 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company ...
Epsilon Announces Full Year 2024 Results
Epsilon Announces Full Year 2024 Results HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported financial results for the fourth quarter and full-year ended December 31, 2024. Full Year and Q4 2024 Highlights: Epsilon - Full Year 2024 & Q4 2024 20242023Q4 2024Q3 2024YoY%QoQ%NRI Production GasMMcf6,1428,3401,7651,304-26%35%OilMbbl187655253186%-3%NGLMbbl6939171778%-2%TotalMmcfe7,6768,9652,1761,727-14%26% Revenues$M Gas 10,78614,8643,9581,904-27%10...
Liquidia Corporation Reports Full Year 2024 Financial Results and Prov...
Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025Advancing pipeline of inhaled treprostinil products in clinical studiesStrengthened financial position by up to $100 million via amendment to existing financing agreement with HealthCare Royalty Partners (HCRx)Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., March 19, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative the...
Liquidia Corporation Strengthens Financial Position by Amending Health...
Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million MORRISVILLE, N.C., March 18, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that it has entered into a sixth amendment to its agreement with HealthCare Royalty (“HCRx”) to provide for up to an additional $100 million of financing in three tranches (the “Sixth Amendment”), subject to certain closing conditions including th...
Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Suppor...
Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome Humanetics’ Novel Radioprotective Agent Being Developed with Funding from Department of Defense as Radiation Medical Countermeasure (MCM) Lifecore to Carry Out Tech Transfer and Analytical Method Activities, including Filling of Pilot Batch CHASKA, Minn. and MINNEAPOLIS, March 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and Human...
Liquidia Corporation to Report Full Year 2024 Financial Results on Mar...
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025 MORRISVILLE, N.C., March 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its full year 2024 financial results on Wednesday, March 19, 2025. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The live webcast will be available on Liquidia's website at . A rebroadcast of the...
Epsilon Energy Ltd. Announces the Following Headlines
Epsilon Energy Ltd. Announces the Following Headlines Board declares dividend of $0.0625 per common shareCompany announces the timing of its 2024 year end earnings release and conference call HOUSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced that its Board of Directors has declared a dividend of $0.0625 per share of common stock (annualized $0.25/sh) to the stock holders of record at the close of business on March 13, 2025, payable on March 31, 2025. All dividends paid by the Company are “eligible dividends” as defi...
Lifecore Biomedical to Participate in Upcoming Investor and Industry C...
Lifecore Biomedical to Participate in Upcoming Investor and Industry Conferences CHASKA, Minn., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in multiple upcoming investor conferences and industry events. Details regarding Lifecore’s participation are as follows: TD Cowen 45th Annual Health Care ConferenceDetails: Paul Josephs, chief executive officer, will deliver a corporate presentation and Lifecore management will ...
Epsilon Energy Ltd. Announces New Share Repurchase Program and Borrowi...
Epsilon Energy Ltd. Announces New Share Repurchase Program and Borrowing Base Redetermination HOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced that its Board of Directors terminated and revoked authority under the normal course issuer bid program which commenced on March 27, 2024. At the same time, the Board of Directors approved a new one-year share repurchase program, under which the Company is authorized to repurchase up to 2,200,876 common shares, representing 10% of the outstanding common shares of Epsilon, for...
Lifecore Biomedical to Participate in 2025 BIO CEO & Investor Conferen...
Lifecore Biomedical to Participate in 2025 BIO CEO & Investor Conference CHASKA, Minn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 2025 BIO CEO & Investor Conference. The conference will take place February 10-11, 2025, in New York, NY. Details regarding Lifecore’s participation are as follows: 2025 BIO CEO & Investor ConferenceDetails: Lifecore management, including Paul Josephs, chief executive officer, and ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.